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Abstract
Background: Percutaneous mitral valve repair (PMVR) is increasingly performed in patients with severe mitral
regurgitation (MR). Post-procedural MR grading is challenging and an unsettled issue. We hypothesised that the
direct planimetry of vena contracta area (VCA) by 3D–transoesophageal echocardiography allows quantifying
post-procedural MR and implies further prognostic relevance missed by the usual ordinal scale (grade I-IV).
Methods: Based on a single-centre PMVR registry containing 102 patients, the association of VCA reduction and
patients’ functional capacity measured as six-minute walk distance (6 MW) was evaluated. 3D–colour-Doppler
datasets were available before, during and 4 weeks after PMVR.
Results: Twenty nine patients (age 77.0 ± 5.8 years) with advanced heart failure (75.9% NYHA III/IV) and severe
degenerative (34%) or functional (66%) MR were eligible. VCA was reduced in all patients by PMVR (0.99 ± 0.46 cm2
vs. 0.22 ± 0.15 cm2, p < 0.0001). It remained stable after median time of 33 days (p = 0.999). 6 MW improved after
the procedure (257.5 ± 82.5 m vs. 295.7 ± 96.3 m, p < 0.01). Patients with a decrease in VCA less than the median
VCA reduction showed a more distinct improvement in 6 MW than patients with better technical result (p < 0.05).
This paradoxical finding was driven by inferior results in very large functional MR.
Conclusions: VCA improves the evaluation of small residual MR. Its post-procedural values remain stable during
a short-term follow-up and imply prognostic information for the patients’ physical improvement. VCA might
contribute to a more substantiated estimation of treatment success in the heterogeneous functional MR group.
Keywords: Percutaneous mitral valve repair, MitraClip, 3D echocardiography, Vena contracta area, Six-minute walk
test, NT-proBNP, Prognosis, Functional mitral regurgitation
Background
Percutaneous mitral valve repair (PMVR) by the
MitraClip©-system (Abbott Vascular) has evolved as
successful alternative to surgery for the treatment of se-
vere mitral regurgitation (MR) in patients at high surgi-
cal risk [1]. Due to edge-to-edge technique at least two
neo-orifices are created by the procedure. Therefore,
established parameters of grading MR recommended by
current guidelines like width of vena contracta and ef-
fective regurgitant orifice area [2–4] are not appropriate
for the complex post-procedural mitral valve anatomy.
The few existing recommendations for MR grading after
PMVR get by with a multimodal approach integrating
parameters as visual assessment of regurgitant jet [5],
which are semi-quantitative and subjectively influenced.
However, vena contracta area (VCA) cannot only be ap-
proximated by the PISA method, but also be directly
measured by cardiac magnetic resonance imaging [6, 7]
or three-dimensional transoesophageal echocardiography
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(3D–TEE) [8]. As 3D–TEE was known to be reliable in
multiple VCA [9], its use for the MR assessment after
PMVR appeared reasonable. Recently, the feasibility of
direct VCA measurement in multiple neo-orifices was
demonstrated with a significant decrease of VCA by
PMVR [10, 11]. Post-procedural VCA is supposed to be
more precise than an ordinal scaled MR grading - as if
the imaging resolution in grade I and II MR is increased.
However, this incremental parameter will serve little
purpose, unless it implies any prognostic information.
To date, data on the prognostic relevance of VCA reduc-
tion for the patients’ functional outcome after PMVR is
lacking. Therefore, we analysed the data of a single-
centre registry containing 102 patients, who underwent
PMVR, in order to examine the association of VCA-
reduction and patients’ functional capacity measured as
six-minute walking distance.
Methods
Study population
The PMVR registry of the University Hospital
Regensburg, Germany, comprises 102 patients, who
underwent the procedure between 04/2012 and 12/2015
and were screened for eligibility. Inclusion criteria for
this study were a standardised six-minute walk test be-
fore and after PMVR as well as stored 3D–TEE colour
Doppler datasets before and during PMVR. For this in-
vestigation, we excluded 73 patients (unavailable six-
minute walk test, 48 subjects; unavailable 3D–TEE
colour Doppler dataset, 17 subjects; insufficient quality
of stored echocardiography for VCA determination, 8
subjects), yielding 29 cases for this analysis.
Clinical parameters
Further information concerning the patients’ health status
was derived from medical records. EuroScoreII and
logEuroScore were calculated [12]. A six-minute walk test
(6MW) was recorded before PMVR and 4 weeks after the
procedure. The test was performed according to the
current statement of the American Thoracic Society [13]
indoors, along a flat, straight, enclosed, seldom travelled
corridor with a hard surface by a trained nurse. The
percutaneous-repair procedure was performed under gen-
eral anaesthesia with the MitraClip System (Abbott Vascu-
lar, Lake Bluff, USA) as previously described [1, 14].
Echocardiography
Two-dimensional transthoracic echocardiography (iE-33
ultrasound system with S5–1 transducer; Philips Medical
Systems, Amsterdam, The Netherlands) was performed in
all patients before and 4 weeks after PMVR. Left ventricular
volumes and left ventricular ejection fraction were calcu-
lated by Simpson’s rule according to recent guidelines [15].
MR was quantified in an integrative view according to the
Endovascular Valve Edge-to-Edge REpair STudy (EVER-
EST) criteria [16]. Information on valve morphology, colour
flow doppler, presence or absence of systolic pulmonary
vein flow, regurgitant volume and regurgitant fraction was
gathered according to recent guidelines [2–4] and com-
bined to grade MR on a scale from mild to severe (I to IV)
[16] to assure comparability to previously published regis-
tries [1, 17–21]. MR immediately after PMVR was graded
from I to IV according to the recommendations of the Ger-
man Cardiac Society (DGK, Additional file 1).
All patients underwent TEE for screening (“before
PMVR”) purpose and during the catheter intervention
providing a dataset immediately after Clip release (“im-
mediately after PMVR”). In a subgroup, a follow-up TEE
was performed 4 weeks after PMVR (“Follow up”). All
images were acquired using an iE-33 ultrasound system
equipped with a 3D–matrix array transducer (X7-2 t).
Screening and follow-up examinations were done in
conscious sedation using benzodiazepines. General an-
aesthesia was established for PMVR. The aetiology of
mitral regurgitation was described as degenerative
(DMR) or functional (FMR).
3D–colour Doppler datasets of the mitral valve were
obtained from mid-oesophageal views. Seven electrocar-
diographically triggered sequential 3D–scans were com-
posed for a 3D–colour full volume dataset. A post-hoc
analysis was performed using commercially available
software packages (Xcelera R3.2 L1, version 3.2.1.820–2011;
Qlab, version 10.5, Philips Medical Systems, Amsterdam,
Netherlands) according to current guidelines [2]. Tissue
priority and tissue threshold were set to factory settings. All
recorded 3D–colour full volume datasets were checked for
lines of disagreement between neighbouring 3D subvo-
lumes (“stitching artefacts”) within the VCA borders or
“dropouts” within the dataset. Care was taken to identify
blooming effects, rendering the Doppler signal larger than
the laminar jet core itself [2]. If artefacts were present, the
patients were excluded from further analyses (8 subjects).
The median 3D frame rate came to 18 Hz, as recom-
mended [22], with a narrow interquartile range (15 to
18 Hz; minimum 8 Hz in 1 subject). VCA was defined as
the cross-sectional area of the narrowest portion of the
proximal regurgitant jet through the closed mitral valve in
early-to mid-systole [8, 23]. The datasets were manually
cropped to provide a direct en-face view perpendicular to
the jet direction. The Nyquist limit was stepwise reduced to
a median of 41.1 cm/s (30.8;41.1) to visualise the colour
flow regurgitant jet with maximum clarity as previ-
ously described [24, 25]. To identify the level of the
narrowest portion of the regurgitant jet, the datasets
were tomographically sliced. A manual planimetry of
the colour Doppler signal was performed (Fig. 1). Care
was taken to measure only the central laminar jet core
[26] of highest, similar, transverse velocity and to
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exclude low-velocity eddies as recommended by previ-
ous publications and the current guidelines [2, 27]. As
after PMVR there used to be multiple jets, VCA of
each jet was determined separately and summed up as
for complex mitral regurgitation [9].
Statistical analysis
Categorical data are expressed as percentages. Their dif-
ferences were tested for significance by Pearson’s chi-
squared test. The distributions of continuous variables
were assessed for normality by Shapiro-Wilk test. If nor-
mally distributed, they are expressed as mean ± standard
deviation. Significance of differences was tested by Student’s
t-test for dependent or independent variables, respectively.
Two-way analysis of variance (two-way ANOVA) was com-
puted to analyse the influence of categorical independent
variables on left ventricular volumes and ejection fraction,
respectively. When normal distribution was rejected, me-
dian and interquartile range (P25; P75) are given and vari-
ables are shown as Turkey box plots. Mann-Whitney U
test, Wilcoxon signed-rank test and Friedman’s test with
consecutive Dunn’s multiple comparison test were per-
formed, as appropriate. Effect size was approximated as
Cohen’s d or Hedges’s g [28] using dedicated software [29].
To assess the reduction in VCA, the ratio (VCAr) was cal-
culated as quotient (VCAr =VCA PMVR/VCA at baseline).
The absolute area of VCA reduction (VCAdiff) was defined
as difference (VCAdiff = VCA baseline–VCA PMVR).
VCAdiff gives the VCA reduction in absolute numbers
[cm2]. Six-minute walk change (6MWc) was calculated as
difference (6MWc= distance after–before PMVR) [30].
Kendall rank correlation coefficient (τ) was calculated to
measure the degree of correlation of non-parametric data.
All statistical analyses were performed using SPSS sta-
tistics version 22 (IBM, Armonk, New York, USA) and
GraphPad Prism Version 6.00 (GraphPad software, La
Jolla, California, USA). Statistical significance was
assigned at a two-sided p-value of less than 0.05.
Power calculation analysis
For post-hoc power analysis G-Power [31] (version
3.1.9.2) was employed. A post-hoc power calculation was
performed for the two main readouts (decrease in VCA
and six-minute walking distance). It revealed sufficient
power (β < 0.0001/0.01) for decrease in VCA/6 MW
(Additional file 2).
Results
Patients’ characteristics
Baseline characteristics of the registry of the University
Hospital Regensburg, Germany, are depicted in Table 1.
Twenty nine patients were included for further analyses
(Table 2). Patients were characterised by higher age
(77.0 ± 5.8 years), advanced heart failure (75.9% in
NYHA class III or IV), severely limited physical capacity
in terms of short 6 MW (257.5 ± 82.5 m), high-burden of
comorbidities and elevated estimated surgical risk. As
depicted by Table 3, Vena contracta width (7.6 ± 1.8 mm)
and effective regurgitant orifice area according to PISA
method (0.45 ± 0.25 cm2) were measured elevated by the
initial TEE. The aetiology of severe MR was considered
DMR in one third (n = 10) and FMR in two thirds (n = 19)
of patients. Four of 10 DMR cases were due to flail
leaflet. In 7 patients, a follow-up 3D–TEE was avail-
able 41 (35;48) days after PMVR.
Effect of PMVR on MR, 6 MW and NT-proBNP levels
The effects of PMVR are depicted in Table 4. MR
was decreased from median grade 4 to 1 in the total
study sample. The effect was also significant analysing
Fig. 1 Vena contracta area determination by 3D–TEE is exemplarily shown for a DMR patient. Shown are MPR views at three time points. Each
MPR view is based on one recorded data set and composed of a fourfold table. Top left (green box): midoesophageal long axis view. Top right
(red): orthogonal plane to green box. Bottom left (blue): 3D–en face view to VCA (traced by red line). Bottom right: multislice representation of 9
evenly distributed slices parallel to 3D–en face view, used to find actual VCA plane. VCA was defined as the central laminar jet core (within red
lines) as defined by current ASE guidelines [2]. Immediately after PMVR the residual regurgitant jet was split into at least two. VCA of each jet was
determined separately and summed up. After PMVR, measurement of one jet is exemplarily shown. VCA: vena contracta area. DMR: degenerative
mitral regurgitation. MR: mitral regurgitation. Σ: two residual jets were summed up. ASE: American Society of Echocardiography
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DMR (decrease from grade 4 (3.5;4.0) to 1 (1;1.5); p < 0.01)
and FMR separately (decrease from grade 4 (3;4) to 1
(0.5;1.5); p < 0.001). Largest residual MR was graded
2.5 (n = 1).
6MW was significantly improved by PMVR. The effect
was particularly pronounced in patients suffering from
DMR (240.4 ± 80.3 m vs. 296.1 ± 63.0 m, Cohen’s d 0.97,
p = 0.013, n = 10). In FMR, effect size was smaller and
slightly missed significance (266.5 ± 84.4 m, Cohen’s d =
0.47, p = 0.053, n = 19). In consequence, PMVR achieved
as early as 4 weeks after the procedure a significant im-
provement of 6 MW with a more distinct effect for DMR.
NT-proBNP blood levels, left-ventricular volumes and
ejection fraction did not show a significant change
(Table 4).
Reduction of VCA by PMVR and consistency between
intra-procedural measurement and follow-up examination
VCA determination was independent of age, sex, left
ventricular ejection fraction, NYHA class and EuroScore.
Table 2 Baseline characteristics of the study sample
Age [years] 77.0 ± 5.8
Female 41.4 (12/29)
Heart rate [bpm] 74 ± 9
Systolic blood pressure [mmHg] 119 ± 19
Diastolic blood pressure [mmHg] 67 ± 14
Body mass index [kg/m2] 25.8 ± 4.2
NT-proBNP [pg/ml] median(P25;75) 3618 (1619; 5782)
Serum creatinine [mg/dl] median(P25;75) 1.1 (1.0; 1.6)
logEuroScore [%] median(P25;75) 18.5 (12.7; 32.2)
NYHA functional class
I 0 (0/29)
II 24.1 (7/29)
III 62.1 (18/29)
IV 13.8 (4/29)
Comorbidities
DCM 10.3 (3/29)
Coronary artery disease 62.1 (18/29)
Diabetes mellitus II 34.5 (10/29)
Medical/Device treatment
High-ceiling diuretics 100 (29/29)
ACE inhibitors 48.3 (14/29)
MRA 62.1 (18/29)
Beta-blocker 89.7 (26/29)
CRT 6.9 (2/29)
Shown are percentage of subjects (number of subjects / total number of
subjects in parentheses) or mean ± standard deviation, if not
indicated otherwise
NYHA New York Heart Association, DCM dilated cardiomyopathy, ACE
angiotensin- converting enzyme, MRA mineralocorticoid receptor antagonist,
CRT cardiac resynchronization therapy
Table 3 Mitral regurgitation in the study sample
MR aetiology Degenerative 34.5 (10/29)
Functional 65.5 (19/29)
MR grading III 17.2 (5/29)
IV 82.8 (24/29)
Vena contracta width [mm] Degenerative 7.30 ± 1.34
Functional 7.79 ± 2.04
ERO [cm2] median (P25;P75) Degenerative 0.45 (0.33; 0.61)
Functional 0.36 (0.27;0.60)
Number of implanted clips 1 51.7 (15/29)
2 48.3 (14/29)
Percentage of subjects (number of subjects / total number of subjects in
parentheses). MR mitral regurgitation, ERO effective regurgitant orifice
calculated by the Proximal- isovelocity surface area (PISA) method
Table 1 Regensburg registry and other published trials and registries including patients treated by the MitraClip system
Regensburg GRASP [17] TRAMI [19] MitraSWISS [18] Pilot Registry [21]a ACCESS-EU [20] EVEREST-II [1]
Year of publication 2016 2016 2014 2014 2013 2011
Participants 102 180 749 74 628 567 184
Female [%] 42.2 38.3 38.6 27 36.9 36.2 38
Age [years] 77.0 ± 5.8 71.6 ± 9.8 76 (10)b 72 ± 12 74.2 ± 9.7 73.7 ± 9.6 67.3 ± 12.8
MR grade III/IV [%] 100 – 93.8 100 86.1c 97.7 96
DMR [%] 28.4 18.3 27.8 38 22.8 20.6 74
FMR [%] 71.6 81.7 71.3 62 72.0 69.3 27
NYHA III/IV [%] 75.5 81.1 89 – 85.5 84.9 52
EuroScore II 5.1 ± 5.9 7.6 ± 6.4 – – – – –
LogEuroScore [%] 26.6 ± 18.0 – 20 (19)f 21 ± 17 20.4 ± 16.7 23.0 ± 18.3 –
Regurgitant orifice area [cm2] 0.40 ± 0.18 – – – 0.43 ± 0.16 – 0.56 ± 0.38
Shown are mean and standard deviation or proportions (if not indicated otherwise)
aTranscatheter Valve Treatment Sentinel Pilot Registry, bmedian (IQR), csevere (graded as mild, moderate, severe). MR mitral regurgitation, DMR degenerative mitral
regurgitation, FMR functional mitral regurgitation, NYHA New York Heart Association functional classification
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Baseline VCA was significantly reduced from 0.89cm2 to
0.17cm2 after PMVR (Table 4). Median VCAr was 0.19
(0.09;0.42). In the subgroup of patients with follow-up
3D–TEE, VCA did not vary between the measure-
ments immediately after PMVR and during follow-up
(p = 0.999, Fig. 2). Their characteristics did not differ
from the group missing a follow-up 3D–TEE examin-
ation with respect to sex, age or clinical manifestation
of MR (Additional file 3).
Correlation of intra-procedural VCA measures and grading
of residual MR
Common ordinal scaled MR grading (1 to 4) and VCA
were compared for evaluating residual MR. There was
significant but weak correlation (τ = 0.361; p = 0.01). As
seen in Fig. 3, the VCAs of all ordinal scaled MR grades
after PMVR spread widely.
VCA reduction as predictor of clinical outcome
The link of MR reduction (VCAr) and an improvement
of the patients’ physical capacity (6MWc) is depicted by
Fig. 4. Using the median VCAr of 0.19 as cut-off value,
patients with a more pronounced procedural VCA re-
duction, mirrored by a VCAr below the median, had a
significantly smaller 6 MWc. Contrary to expectations,
data imply a more modest success for functional im-
provement in patients, whose technical success in VCA
reduction was essentially more distinct.
To scrutinize possible underlying causes, two groups
divided by the median VCAr were compared. Explora-
tive data analysis did not yield significantly differing re-
sults between groups except for the absolute area of
VCA change (VCAdiff ) (Additional file 4). VCAr and
VCAdiff were correlated with a negative Kendall rank
correlation coefficient (τ = −0.51, p = 0.0001). Thus, as
VCAr decreases, VCAdiff increases, which seems quite
conclusive.
Table 4 Effect of PMVR on mitral regurgitation, 6-min walk and LV remodelling
Before PMVR After PMVR p-value
MR grade median (P25;P75) 4 (3.5;4.0) 1 (0.5;1.5) < 0.001
6 min walk [m] 257.5 ± 82.5 295.7 ± 96.3 < 0.01
VCA (3D) [cm2] median (P25;P75) 0.89 (0.65;1.33) 0.17 (0.09;0.37) < 0.0001
NT-proBNP [pg/ml] median(P25;75) 3618 (1619;5782) 3247 (2273;4693) 0.954
LV end-diastolic volume [ml/m2] 85.0 ± 26.5 79.4 ± 23.2 0.17
LV end-systolic volume [ml/m2] 49.8 ± 22.2 44.7 ± 17.4 0.11
LV ejection fraction [%] 42.5 ± 12.5 43.6 ± 10.1 0.51
PMVR decreased mitral regurgitation and improved six-minute walking distance in a follow-up examination 4 weeks after the intervention. NT-proBNP and
left-ventricular volumes and ejection fraction remained unchanged. Shown are mean ± standard deviation, if not indicated otherwise
PMVR percutaneous mitral valve repair, LV left ventricular, MR mitral regurgitation, VCA (3D) vena contracta area determined by direct planimetry in a 3D–coulor
Doppler full volume
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Fig. 2 Vena contracta area remains stable 4 weeks after PMVR. Shown
are values of seven patients with follow-up TEE after 4 weeks. *p < 0.05
Dunn’s multiple comparison test with ##p < 0.01 (Friedman test)
Fig. 3 Ordinal scaled grading of residual mitral regurgitation (left y-axis)
faces a wide spread of remaining vena contracta area (right y-axis).
n= 29. Ladder plot. PMVR: percutaneous mitral valve repair. MR: mitral
regurgitation. VCA: vena contracta area
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Based on these observations, we speculated, whether
effects of very large VCA could drive our results. The
75% quantile of VCAdiff was used as cut-off to differ
between low and high VCAdiff (75% quantile =
1.05 cm2). Patients, who were suffering from FMR and
exhibited a VCAdiff below the 75% quantile, had a
post-procedural increase in six-minute walking distance
(+43.57 ± 49.53 m, n = 14). By contrast, patients with
larger VCAdiff came to a decreased six-minute walk
distance after PMVR (−12.20 ± 76.59 m, n = 5). The dif-
ference showed a strong effect (Hedges’s g = −0.977)
slightly missing significance (p = 0.078).
There was no difference between small and large
VCAdiff regarding changes in post-procedural left ven-
tricular volumes or function compared to baseline (p for
end-diastolic volume/end-systolic volume/ejection frac-
tion = 0.97/0.68/0.45, 2-way ANOVA).
Thus, in large, potentially long-standing FMR, our data
was indicative for a less beneficial effect than in smaller
FMR with regard to the patients’ functional outcome.
Discussion
In this study assessing prognostic implications of VCA
reduction, we observed the following key findings:
1) Patients’ six-minute walking distance was
improved already 4 weeks after PMVR with a
more pronounced effect for DMR.
2) VCA is significantly reduced by PMVR and its
dimensions remain stable during a short-term
follow-up.
3) VCA measurement immediately after PMVR
improves the evaluation of small remaining MR by
implying prognostic relevance for the patients’
physical capacity measured as 6MWc.
Study sample and treatment success in the context of
published literature
The baseline characteristics of the Regensburg PMVR
Registry reported for the first time by our study were
quite comparable to currently published results of
several registries [1, 17–21] (Table 1) mirroring the real-
life practice. The use in FMR was consistently reported
higher than in the initial EVEREST-II trial [1]. Remark-
ably, in our data the effect of PMVR on patients’ func-
tional capacity (6 MW) was more pronounced in DMR.
NT-proBNP as marker of left ventricular wall stress and
predictor of cardiovascular outcome [32] was elevated
before and after PMVR without significant change in
line with a current publication reporting no benefit of
PMVR with regard to NT-proBNP levels in 144 patients
[33]. Nevertheless, the field is still not settled due to
contrary results in smaller samples [34]. Heterogeneous
comorbidities might explain nonresponse of NT-proBNP
after PMVR [35].
VCA as independent measurement for quantifying
residual MR after PMVR
In patients with high grade MR and elevated surgical
risk, PMVR is increasingly used leading to significant
improvements in clinical outcome [1, 14, 19]. The edge-
to-edge technique of PMVR alters the complex anatomy
of the mitral valve in DMR [36] and FMR [10] and cre-
ates at least two neo-orifices. The remaining MR is split
into often very eccentric regurgitant jets (Fig. 1) and
common parameters of echocardiographic MR assessment
as width of vena contracta and effective regurgitant orifice
area are not applicable. The sparse existing guidelines (e.g.
of the German Cardiac Society [5], Additional file 1) rec-
ommend a multimodal approach integrating parameters
determined by echocardiography (visual grading of regur-
gitant jet), right-heart catheterization (v-wave) and left
ventriculography (regurgitant volume) with echocardiog-
raphy as mainstay. Though in real-life most often used
during PMVR, the qualitative as well as quantitative as-
sessment of the regurgitant jets using colour-Doppler is
imprecise and tents to an overestimation of remaining
MR in the situation of multiple jets [37]. Even before the
launch of PMVR, VCA was known for several strengths in
the assessment of high-grade MR [8]: In an in vitro model
of MR, VCA provided the strongest correlation with
known orifice area (r = 0.92, p < 0.001) compared to other
echocardiographic measurements, which could be trans-
lated to a prospective study comprising 61 patients with at
least mild MR of different aetiology: feasibility and
Fig. 4 Functional success of PMVR is more pronounced, when vena
contracta area is less reduced then the median of the study sample.
n = 29. Median VCAr = 0.1868. Turkey boxplot with + marking the
mean. *p < 0.05. VCAr = ratio of vena contracta area immediately
after PMVR / before PMVR. 6 MWc = six-minute walk distance after
PMVR – before PMVR. PMVR: percutaneous mitral valve repair
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reproducibility was established yielding satisfying interob-
server agreement (r = 0.96; 0.05 ± 0.02 cm2) [38]. In the
same year, a further prospective study including 57 pa-
tients with relevant MR of different aetiologies [39] re-
ported feasible measurements in all patients within 2.6
± 0.7 min of measuring time and ruled out significant
interobserver variability (r = 0.97, 0.04 ± 0.09 cm2).
VCA is reliable in multiple jet areas, too [9].
Considering VCA measurement after PMVR, Altiok et
al. set the stage by using VCA determined by 3-D-TEE
to analyse the procedural effects of PMVR in FMR [11]
with acceptable feasibility and reproducibility. In 2017,
these data were confirmed [10] by a retrospective study
comprising 97 heart failure patients with severe MR
undergoing MitraClip therapy reporting adequate inter-
observer variability (r = 0.95, p < 0.001). Comparing VCA
to the common ordinal scale of MR grading, our data
show that within each MR grade VCA still spreads. It
highlights the potential of VCA measurement to in-
crease the resolution of residual MR grading.
The intraprocedural TEE has to face the inherent
problem of anaesthesia, which changes cardiac pre-
and afterload influencing mitral valve function [40].
Interestingly, VCA did not change in our dataset be-
tween the intraprocedural TEE in general anaesthesia
and a follow-up examination, which has been done in
conscious sedation using benzodiazepines 4 weeks later.
These results might indicate a quite comparability of both
examinations regarding particularly VCA measurement.
VCA as predictor of post-procedural outcome
The need for a reliable measurement of residual MR is
underscored by its prognostic importance: data from the
MitraSWISS registry revealed residual MR severity after
PMVR as significant predictor of reduced survival after
2 years [18]. They suggested that MR should be reduced
as far as possible. It has to be stressed that these analyses
relied on ordinal scaled grading of residual MR by com-
bined methods. In 2017, Alessandrini et al. measured
VCA in FMR patients after PMVR. Dichotomised VCA
(≥ 0.25cm2, upper vs. lower and middle tertile of their
sample) was associated with mortality during a median
follow-up of 13.4 months (HR = 3.8, CI 1.9–7.8) [10].
Our data confirm prognostic implication of remaining
MR. However, since MR severity is very dynamic, we
hypothesised beyond previous published analyses, that
there might be differences in outcome depending on
pre-procedural MR anatomy. Therefore, we wanted to
assess the association of decreasing VCA (ratio post/
pre-procedural) and the patients’ outcome, which was
measured as gain in 6 MW. Strikingly, we observed a
more pronounced increase in 6 MW 4 weeks after
PMVR in patients, whose VCA was less reduced by
PMVR. This paradoxical result was predominantly
driven by the negative outcome of patients suffering
from FMR with a large absolute difference between
their VCA before and immediately after PMVR (> 75%
quantile, > 1.05cm2). These patients lacking functional
improvement after PMVR had considerably large func-
tional regurgitant jets measured as VCA 2.5-fold higher
than the cut-off value defining the edge between mod-
erate and high-grade disease [8, 39, 41]. It is tempting
to speculate whether PMVR strictly decreasing VCA
might be less beneficial in very-large, presumably
chronic and long-standing FMR than at an earlier point
of intervention as additionally suggested by recent data
[42]. For FMR comprises a variety of entities as a result
of cardiac remodelling [43–46]. Thus, our study might
suggest with VCA an interesting, objective, measurable
pre-procedural criterion for PMVR planning. Nonethe-
less, this issue awaits further, strongly required prospective
evaluation as patient selection in FMR for PMVR is a cen-
tral and current problem and valid parameters for this
purpose are strongly needed.
Strengths and limitations
Strengths of our study include precise measurement of
MR by the direct planimetry of VCA using 3D–TEE,
which has already been shown to be accurate [8] and
feasible in multiple jets [9] even after PMVR [10, 11].
However, data on DMR has been lacking to date. Fur-
thermore, nor VCA neither another method has been
used until now to assess prognostic implication of re-
sidual MR concerning functional treatment success.
Thus, a novel approach was chosen and provided new
insights. Furthermore, the recorded follow-up 3D–TEE
examinations permitted an analysis of stability during
short-term follow-up.
However, some limitations warrant consideration: re-
duction in regurgitant volume immediately after PMVR
could similarly be discussed as another potential marker
of later clinical outcome. Regurgitant volume is esti-
mated as difference of stroke volumes measured at the
LVOT and mitral valve level [47] or alternatively, by
magnetic resonance imaging. Both methods are applic-
able even after MitraClip [48]. Unfortunately, we do not
have this data to compare it with VCA reduction. This
issue awaits future studies.
The retrospective design with a moderate-sized num-
ber of participants limits analytic options. Neverthe-
less, it is the first study in the field addressing this
current and highly relevant issue by testing a clear and
unambiguous hypothesis and using a precise measur-
ing method as well as a quantifiable, relevant outcome
variable. Thus, it allowed a thorough statistical analysis
even in a medium-sized sample with appropriate statis-
tical power.
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Still, due to the small sample size, little effects can be
missed and non-significant results do not rule out a po-
tentially overseen small effect. Nonetheless, our study
may report on significant effects yielded by PMVR.
However, albeit significance was computed, some justi-
fied concerns about generalizability might remain be-
cause of the small sample size and should by answered
by further research. To offer valid information at the
moment, we provide also estimates of effect sizes beside
p-values, which could facilitate a-priori power calcula-
tion for future prospective studies.
The study emphasised the importance of precise echo-
cardiographic imaging in PMVR, although all large regis-
tries ignore new measurements of residual MR as VCA
(Table 1). It is our hope that our results will help to de-
sign future prospective studies, which further elucidate
the prognostic meaningfulness of residual MR particu-
larly in outsized FMR.
Conclusions
The current study confirms direct planimetry of VCA by
3D–TEE as a feasible method to quantify DMR as well
as FMR in the situation of multiple neo-orifices after
PMVR. PMVR reduces VCA and improves significantly
6 MWc as early as 4 weeks after the procedure with a
more pronounced effect in DMR. The values of VCA de-
termined immediately after Clip release remain stable
during a short-term follow-up of 4 weeks and they imply
prognostic relevance for the patients’ physical capacity
measured as 6 MWc. There is some evidence that in
FMR as heterogeneous disease VCA might contribute to
a more substantiated estimation of treatment success.
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